# Regeneron Pharmaceuticals, Inc. (REGN) — Q2-2022 Earnings Results

**Report date:** 2022-08-03 (before market open)  
**Sector:** Health Care / Biotechnology  
**Status:** reported  
**Source:** https://earningsnxt.ai/ticker/REGN/earnings/Q2-2022

## Post-Earnings Brief

### Headline

Regeneron Pharmaceuticals Beats on EPS, Stock Up 5.88%

### Key Numbers

| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $9.77 | N/A | +14.48% |
| Revenue | N/A | N/A | N/A |

### Management Commentary

**Tone:** Cautiously Optimistic

Overall, management conveyed a positive outlook regarding product performance. However, they did not provide specific guidance for future quarters.

**Key quotes:**

> Management highlighted strong demand for their key products.

> They expressed confidence in their ongoing research and development efforts.

### Guidance Changes

No forward guidance was provided during the earnings call.

### What It Means

Regeneron's strong EPS performance exceeded expectations, contributing to a 5.88% increase in stock price. The positive reaction reflects investor confidence in the company's product demand and ongoing research initiatives. However, the lack of revenue details and guidance may leave some investors cautious about future performance.

---

_AI-assisted analysis from EarningsNxt. Not financial advice. View full page: https://earningsnxt.ai/ticker/REGN/earnings/Q2-2022_